PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost invariably encounter roadblocks, often exposing unresolved questions in the basic understanding of the target
PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis. This book details key discoveries in the area, their impact and future directions.
PI3K - From the bench to the clinic and back.- Oncogenetic mutations of PIK3CA in human cancers.- Structural effects of oncogenic PI3Kalpha mutations.- Comparing the roles of the p110a and p110b isoforms of PI3K in signaling and cancer.- Phophatidylinositol 3-kinase (PI3K): the oncoprotein.- AKT Signaling in Physiology and Disease.- Faithfull modeling of PTEN loss driven diseases in the mouse.- PI3K as a target for therapy in haematological malignancies.- Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors.- From the bench to the bed side: PI3K pathway inhibitors in clinical development.- New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling From a New Generation of Tor Kinase Domain Inhibitors (TORKinibs).- Small molecule inhibitors of the PI3-kinase family.- Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.- Subject indexContents of sister volume 1:PI3K Book Introduction.- PDK1: The major transducer of PI 3-kinase actions.- Protein Kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway.- Regulatory subunity of class IA PI3K.- The Regulation of Class IA PI 3-kinases by Inter-Subunit Interactions.- Phosphoinositide signalling pathways in metabolic regulation.- Role of RAS in the regulation of PI 3-kinase.- More than just kinases: the scaffolding function of PI3K.- PI3Kl“+